Medicxi, RA Cap­i­tal join $30M round for Dutch biotech's late-stage trans­plan­ta­tion med

Bring­ing Medicxi and RA Cap­i­tal Man­age­ment in­to the fold, Xenikos has clinched $30 mil­lion in Se­ries B fund­ing to push its trans­plan­ta­tion med through the last big re­search lap be­fore ap­proach­ing reg­u­la­tors’ doors.

Ni­jmegen, the Nether­lands-based Xenikos is de­vel­op­ing a ther­a­py for steroid-re­sis­tant acute graft-ver­sus-host dis­ease called T-Guard, which helps re­store bal­ance in the im­mune sys­tem fol­low­ing hematopoi­et­ic stem cell trans­plan­ta­tion. With the new funds, the biotech plans to con­duct Phase III tri­als in both the US and EU — where T-Guard has been des­ig­nat­ed an or­phan drug — as well as in­vest in com­mer­cial scale pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER